Are you looking for a reliable partner to access over 15 pharmaceutical markets in CEE and Switzerland? Acting as a one-stop shop we commercialize successfully both prescriptions drugs and consumer healths products. Since 1959, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Our teams love what they do and are happy to go the extra mile for our partners. Watch our video and learn why Ewopharma is your partner of choice. Read more about our expertise and portfolio. www.ewopharma.com
Ewopharma
Pharmaceutical Manufacturing
Schaffhausen, SH 4,144 followers
YOUR BRIDGE TO NEW MARKETS
About us
Ewopharma is the successor company to M.R. Leclerc & Co., founded in 1959. From the start, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Much has changed in the region since 1959 – both economically and politically – and over this period we have gained an in-depth understanding of the markets and an esteemed standing there. While we started out purely as a marketing partner for pharmaceutical companies, we have since acquired and launched proprietary products. Our brand Revalid® – a product line for holistic hair care and hair loss treatment–was developed in 1992 in Switzerland. In 2011, we acquired Irish healthcare company Newport Pharmaceuticals Ltd. giving us full ownership of the antiviral drug Isoprinosine® in 2011.Overseen by our head office in Schaffhausen, Switzerland, we now channel our industry knowledge and experience into the successful placement of both Ewopharma and partner brands in our target markets. In 2004, we joined the RX-Alliance, a professional cooperation network of successful pharmaceutical companies active in selected European markets.
- Website
-
http://www.ewopharma.com
External link for Ewopharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Schaffhausen, SH
- Type
- Privately Held
- Founded
- 1959
Locations
Employees at Ewopharma
-
Shila Schneider, PhD, MBA
Senior Business Development & Transaction Manager @Ewopharma AG (Senior Staff, Prokura) | Münchener Ausbildung zum Wirtschaftsmediator
-
Konrad Witek
-
Alina Ceocea-Iancu
Business Unit Manager Pharma Romania & The Republic of Moldova
-
Cristian Stanciu
Country Manager at Ewopharma AG
Updates
-
We are thrilled to announce that Ewopharma will be participating at the SWISS HLG Conference 2024. The conference will take place from 26-28 May 2024. We look forward to connecting with fellow professionals and advancing healthcare together! https://lnkd.in/diuD_Q7
-
Two weeks left until the BIO-Europe Spring starts. Visit us at our booth at the Swiss Pavilion. We look forward to discuss partnership and collaboration opportunities with you in Barcelona! https://lnkd.in/diuD_Q7
ewopharma: Meet us
ewopharma.com
-
Ewopharma will participate at BIO-Europe Spring in Barcelona from 18-20 March 2024. Join us for a partnering meeting or meet us at our booth at the SWISS Pavilion to discuss collaboration opportunities for bringing innovative therapies to our markets in Switzerland and Central Eastern Europe. https://lnkd.in/diuD_Q7
ewopharma: Meet us
ewopharma.com
-
WE ARE HIRING An unserem Hauptsitz in Schaffhausen suchen wir per sofort zur Ergänzung unseres dynamischen, internationalen Teams im Bereich OTC/Consumer Health eine Marketing-Persönlichkeit mit Hands-on Mentalität als: PRODUCT MANAGER OTC/CHC 80-100% https://lnkd.in/d4ZKWAg Sehen Sie sich in dieser Position? Besuchen Sie unsere Website und reichen Sie Ihre Bewerbung ein. #hiring #jobs #ewopharma
Careers
ewopharma.com
-
Ewopharma reposted this
Ewopharma is pleased to announce the expansion of its collaboration with Can-Fite Biopharma by adding Pancreatic Cancer, a new indication for development candidate Namodenoson, to the parties’ licensing agreement. Pancreatic cancer is an area with high unmet medical need, and Can-Fite has already initiated a Phase 2a study in patients with pancreatic carcinoma, who have failed first-line treatment. https://lnkd.in/dkfPQ9Ga
-
Ewopharma is pleased to announce the expansion of its collaboration with Can-Fite Biopharma by adding Pancreatic Cancer, a new indication for development candidate Namodenoson, to the parties’ licensing agreement. Pancreatic cancer is an area with high unmet medical need, and Can-Fite has already initiated a Phase 2a study in patients with pancreatic carcinoma, who have failed first-line treatment. https://lnkd.in/dkfPQ9Ga
-
In two weeks the BIO-Europe Digital Partnering event will take place. Meet us online! https://lnkd.in/diuD_Q7
ewopharma: Meet us
ewopharma.com
-
Für August 2024 haben wir eine LEHRSTELLE ALS KAUFFRAU/KAUFMANN EFZ ODER KAUFFRAU/KAUFMANN EFZ MIT INTEGRIERTER BERUFSMATURITÄT in Schaffhausen zu vergeben. Wir bieten eine abwechslungsreiche Ausbildungszeit in einem internationalen Umfeld. Weitere Informationen findet man hier: https://lnkd.in/d4ZKWAg
Careers
ewopharma.com
-
Join Ewopharma for a meeting at BIO-Europe Digital Partnering November 14-15, where we will discuss partnership and collaboration opportunities to bring innovative therapies to Switzerland and Central Eastern Europe. https://lnkd.in/diuD_Q7
ewopharma: Meet us
ewopharma.com